Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
G protein-coupled receptor 87 (GPR87) is an orphan member of the rhodopsin-like (class A) GPCR superfamily, located on human chromosome 3q25. It is characterized by seven transmembrane domains, conserved motifs (such as the DRY motif), and has been identified as a receptor for lysophosphatidic acid (LPA). GPR87 is overexpressed in multiple cancer types, notably squamous cell carcinoma of the lung and bladder, and is essential for tumor cell survival, particularly under stress conditions mediated by p53. Its involvement in signal transduction, cell survival, and metabolic regulation underscores its promise as a therapeutic target in oncology. However, as an orphan receptor, its endogenous ligand was initially unknown and drug development is ongoing, with no approved antagonists or modulators yet.
Approaches under investigation include: Antibody-based (mAb) inhibition of cell-surface GPCRs; Small molecule antagonists or inverse agonists blocking signal transduction; RNAi/gene knockdown or gene editing for target inactivation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on G protein-coupled receptor 87 (GPR87).